drugset
drugset / Trial / NCT01147406

Safety and Tolerability Study of N6022 in Healthy Subjects

NCT01147406 ↗

Phase 1 Completed 41 enrolled Nivalis Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of N6022 in healthy subjects.

Timeline

Start
2010-08
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject N6022 Small molecule 5 mg —
Subject N6022 Small molecule 15 mg —
Subject N6022 Small molecule 45 mg —

Indications

No indication recorded.